We are proud to announce the acquisition of Oncolines, a Netherlands-based CRO that provides early biology services and cell-line profiling assays. Oncolines is Symeres’ third acquisition in the past ten months and will take group revenues to over €100m.
Oncolines, part of NTRC Holding, and based in Oss, the Netherlands, is a high-quality CRO that offers precision medicine services in the fields of oncology and immunotherapy. Their mission is to help clients bring improved and novel therapies to the right patient population, faster.
Clients are clinical and pre-clinical biopharma customers that seek to differentiate their drug candidates. The company offers cancer cell-line profiling assays through a panel of over 200 cell lines, combination studies to identify novel synergies and mechanistic cell biology.
The business employs approximately 20 people and will remain under management of the Founder and current Managing Director, Dr. Guido Zaman. Oncolines is located 25 km from Symeres HQ, further contributing to the seamless integration of its offering into Symeres’ portfolio.
This acquisition complements Symeres’ drug discovery capabilities with high-quality biology and biophysics capabilities in oncology. Symeres will extend Oncolines’ services across the broader Symeres platform, resulting in a more integrated offering to better service new and existing customers.
Dr. Guido Zaman, Managing Director of Oncolines, stated: “We are excited to be joining Symeres, a leading transatlantic drug discovery contract research, development and manufacturing organization with over 30 years of drug discovery and synthetic and medical chemistry expertise. Partnering our biology and cell-line profiling capabilities with Symeres’ larger scale in North America and Europe is a natural fit, both for our employees and customers.”
Dr. Eelco Ebbers, Co-Founder and CEO of Symeres, stated: “We are delighted to welcome Oncolines into the Symeres Group. Working with Guido has been a rewarding experience and there is a clear cultural fit and alignment in strategic vision. The acquisition captures an exciting opportunity for Symeres in oncology and immunotherapy as well as personalized medicine.”
Read the full press release here
